Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
AstraZeneca PLC (GB:AZN)
LSE:AZN
AZN Stock Chart & Stats
Day’s Range― - ―
52-Week Range9,670.00p - 13,388.00p
Previous CloseN/A
Volume91.53K
Average Volume (3M)2.89M
Market Cap
£182.78B
Enterprise Value183.25B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)33.2
Beta0.96
Next Earnings
Apr 29, 2025EPS Estimate
175.87Last Dividend Ex-Date
Feb 20, 2025Dividend Yield1.98%
Share Statistics
EPS (TTM)3.56
Shares Outstanding1,550,581,200
10 Day Avg. Volume3,532,638
30 Day Avg. Volume2,891,834
Standard Deviation0.06
R-Squared0.10
Alpha0.00896
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4.63
Price to Cash Flow (P/CF)20.40
P/FCF Ratio28.60
Enterprise Value/Market Cap1.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit4.18
Enterprise Value/Ebitda10.64
Forecast
1Y Price Target
13,681.82pPrice Target Upside16.90% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
---
Bulls Say, Bears Say
Bulls Say
Oncology AssetsAstraZeneca has expressed excitement about assets in oncology, particularly Camizestrant and AZD0486, highlighting strong data and opportunities.
Pipeline ReadoutsA catalyst rich year: five high-profile readouts, with the scope to drive meaningful revisions and take AZN closer to its $80bn revenue ambition by 2030.
Sales GrowthFY'25 presents another year of double-digit bottom line growth, with continued strong product sales momentum.
Bears Say
Competitive LandscapeBaxdrostat is noted for its potential competitive advantage due to its longer half-life, offering true 24-hour blood pressure coverage.
Market ValuationValuation at approximately 14 times 2026 expected earnings looks attractive, with potential for rerating to 18 times.
Pipeline RisksPotential for upside from a partnership agreement and several high-value pipeline readouts, yet it poses risks if outcomes do not meet expectations.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.02% Insiders
14.32% Mutual Funds
0.01% Other Institutional Investors
77.06% Public Companies and Individual Investors
AZN FAQ
What was AstraZeneca PLC’s price range in the past 12 months?
AstraZeneca PLC lowest share price was 9670.00p and its highest was 13388.00p in the past 12 months.
What is AstraZeneca PLC’s market cap?
AstraZeneca PLC’s market cap is £182.78B.
When is AstraZeneca PLC’s upcoming earnings report date?
AstraZeneca PLC’s upcoming earnings report date is Apr 29, 2025 which is in 67 days.
How were AstraZeneca PLC’s earnings last quarter?
AstraZeneca PLC released its earnings results on Feb 06, 2025. The company reported 1.657p earnings per share for the quarter, beating the consensus estimate of 1.641p by 0.016p.
Is AstraZeneca PLC overvalued?
According to Wall Street analysts AstraZeneca PLC’s price is currently Undervalued.
Does AstraZeneca PLC pay dividends?
AstraZeneca PLC pays a Annually dividend of 167.999p which represents an annual dividend yield of 1.98%. See more information on AstraZeneca PLC dividends here
What is AstraZeneca PLC’s EPS estimate?
AstraZeneca PLC’s EPS estimate is 175.87.
How many shares outstanding does AstraZeneca PLC have?
AstraZeneca PLC has 1,550,581,200 shares outstanding.
What happened to AstraZeneca PLC’s price movement after its last earnings report?
AstraZeneca PLC reported an EPS of 1.657p in its last earnings report, beating expectations of 1.641p. Following the earnings report the stock price went up 5.932%.
Which hedge fund is a major shareholder of AstraZeneca PLC?
Currently, no hedge funds are holding shares in GB:AZN
---
AstraZeneca Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
13,681.82p (16.90% Upside)
13,681.82p (16.90% Upside)
Insider Transactions
Bought Shares
Worth £151.1K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
14.80%
12-Months-Change
Fundamentals
Return on Equity
17.25%
Trailing 12-Months
Asset Growth
4.72%
Trailing 12-Months
Company Description
AstraZeneca PLC
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The company sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
---
AZN Stock 12 Month Forecast
Average Price Target
13,681.82p
▲(16.90% Upside)
Technical Analysis
Best Analysts Covering AZN
1 Year
1 Year Success Rate
27/29 ratings generated profit
1 Year Average Return
+16.79%
upgraded a buy rating 9 days ago
Copying Matthew Weston's trades and holding each position for 1 Year would result in 93.10% of your transactions generating a profit, with an average return of +16.79% per trade.
---